EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aimmune Therapeutics's enterprise value is $2,086.61 Mil.
Aimmune Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 was $-269.37 Mil. Therefore, Aimmune Therapeutics's EV-to-EBITDA for today is -7.75.
The historical rank and industry rank for Aimmune Therapeutics's EV-to-EBITDA or its related term are showing as below:
AIMT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.75 Med: -3.33 Max: -2.41
Current: -7.75
During the past 7 years, the highest EV-to-EBITDA of Aimmune Therapeutics was -2.41. The lowest was -7.75. And the median was -3.33.
AIMT's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.14
vs AIMT: -7.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Aimmune Therapeutics EV-to-EBITDA Historical Data
The historical data trend for Aimmune Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aimmune Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, Aimmune Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aimmune Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aimmune Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aimmune Therapeutics's EV-to-EBITDA falls into.
Aimmune Therapeutics's current Enterprise Value is $2,086.61 Mil.
Aimmune Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-269.37 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aimmune Therapeutics's PE Ratio for today is calculated as:
Aimmune Therapeutics's share price for today is $34.49.
Aimmune Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Aimmune Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Aimmune Therapeutics (Aimmune Therapeutics) Business Description
Aimmune Therapeutics Inc is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AIMT has been successfully added to your 